BMJ  2007;334:1181 (9 June), doi:10.1136/bmj.39238.353657.DB

News

Drugs "refund" scheme proposed for England and Wales

Susan Mayor

London

The first 150 words of the full text of this article appear below.

The drugs advisory body for England and Wales has recommended a "refund" scheme in which the manufacturer of bortezomib (Velcade) would reimburse the NHS for the cost of the drug in patients who do not respond to treatment.

The refund scheme, proposed by the National Institute for Health and Clinical Excellence (NICE), could signal a way for the NHS to cope with funding the rapidly growing range of new and expensive drugs. It was suggested by the company making bortezomib, Janssen-Cilag, as part of its appeal against NICE's previous recommendation that the drug was not cost effective.

NICE's independent advisory committee agreed and recommended in draft guidance published this week that all suitable patients with progressive multiple myeloma should be offered bortezomib. Patients who show a full or partial response should continue treatment, with the costs of treatment being met by the NHS. Patients showing a minimal or no response . . . [Full text of this article]


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to StumbleUpon StumbleUpon   Add to Technorati Technorati    What's this?

Relevant Article

Personalised medicine requires regulatory change, former FDA head says
Bob Roehr
BMJ 2008 336: 1461. [Extract] [Full Text]

Rapid Responses:

Read all Rapid Responses

good old days of no cure no pay
Pantula SRK Sastry
bmj.com, 9 Jun 2007 [Full text]
Access jobs at BMJ Careers
Whats new online at Student BMJ